Liujun

Jun Liu is a professor at State Key Laboratory of Natural Medicines, China Pharmaceutical University. She received her Ph.D. degree in Pharmacology from China Pharmaceutical University. She worked as a profound pharmacologist on immunology research. In recent years, the main research direction is to target the novel immune checkpoint protein VISTA, to carry out the molecular mechanism of tumor immunity and autoimmune diseases and new drug discovery research, and obtain a series of innovative research results.His research results have been published in PNAS, British Journal of Pharmacology, Cell biology and Toxicology, Frontiers in immunology and other SCI journals.

“Co-expression of immune checkpoints in glioblastoma revealed by single-nucleus RNA sequencing and spatial transcriptomics” —published in Computational and Structural Biotechnology Journal, 2024.

“Imatinib and M351-0056 enhance the function of VISTA and ameliorate the development of SLE via IFN-I and noncanonical NF-κB pathway”— published in Cell biology and toxicology, 2023.

“ Non-redundant regulation of murine T cell responses by VISTA and PD-1 immune-checkpoints.” —publishen in PNAS, 2015.

“ M351-0056 is a novel low MW compound modulating the actions of the immune-checkpoint protein VISTA.” —published in Br J Pharmacol.，2021.

Study the mechanism of immune checkpoint VISTA in tumor immunity and autoimmune diseases and develop the new drug targeting VISTA.